高端疫苗 (6547.TWO)

52.30 +0.10 (+0.19%) 收市：01:30PM CST

高端疫苗

No. 16, Hu Road
7th Floor Lane 120 Section 1
Taipei 114
Taiwan
886 2 7745 0830
https://www.medigenvac.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Yu-Ping Yang	Chief Financial Officer	無	無	無
Mr. Shih-Shen Lee	Executive Vice President of Operations Business Unit	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

公司管治

截至 無 止，高端疫苗 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。